“AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients.

The British pharma giant said Wednesday that the trial for Camizestrant showed statistically significant and clinically meaningful improvement in progression-free survival compared with the standard-of-care treatment.”

From Wall Street Journal.